{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(1)"],"submitter":["Ascierto PA"],"funding":["This work was supported by Bristol-Myers Squibb (no grant number is applicable)."],"pubmed_abstract":["<h4>Background</h4>We have previously reported significantly longer overall survival (OS) with ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with advanced melanoma, with higher incidences of adverse events (AEs) at 10 mg/kg. This follow-up analysis reports a 5-year update of OS and safety.<h4>Methods</h4>This randomized, multicenter, double-blind, phase III trial included patients with untreated or previously treated unresectable stage III or IV melanoma. Patients were randomly assigned (1:1) to ipilimumab 10 mg/kg or 3 mg/kg every 3 weeks for 4 doses. The primary end point was OS.<h4>Results</h4>At a minimum follow-up of 61 months, median OS was 15.7 months (95% CI 11.6 to 17.8) at 10 mg/kg and 11.5 months (95% CI 9.9 to 13.3) at 3 mg/kg (HR 0.84, 95% CI 0.71 to 0.99; p=0.04)."],"journal":["Journal for immunotherapy of cancer"],"pagination":["e000391"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7279645"],"repository":["biostudies-literature"],"pubmed_title":["Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma."],"pmcid":["PMC7279645"],"pubmed_authors":["Grange F","Schadendorf D","Chiarion-Sileni V","Lebbe C","Hamid O","Garbe C","Svane IM","McNeil C","Loquai C","Hoeller C","Simsek B","Thomas L","Pikiel J","Mortier L","Liszkay G","Rutkowski P","Hosein F","Ascierto PA","Bastholt L","Dreno B","Ferraresi V","Maio M","Mackiewicz A","Gutzmer R","Grob JJ","Smylie M","Nyakas M","Del Vecchio M","Arance A","Robert C"],"additional_accession":[]},"is_claimable":false,"name":"Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma.","description":"<h4>Background</h4>We have previously reported significantly longer overall survival (OS) with ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with advanced melanoma, with higher incidences of adverse events (AEs) at 10 mg/kg. This follow-up analysis reports a 5-year update of OS and safety.<h4>Methods</h4>This randomized, multicenter, double-blind, phase III trial included patients with untreated or previously treated unresectable stage III or IV melanoma. Patients were randomly assigned (1:1) to ipilimumab 10 mg/kg or 3 mg/kg every 3 weeks for 4 doses. The primary end point was OS.<h4>Results</h4>At a minimum follow-up of 61 months, median OS was 15.7 months (95% CI 11.6 to 17.8) at 10 mg/kg and 11.5 months (95% CI 9.9 to 13.3) at 3 mg/kg (HR 0.84, 95% CI 0.71 to 0.99; p=0.04).","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jun","modification":"2026-06-08T06:50:29.452Z","creation":"2026-06-08T03:14:34.109Z"},"accession":"S-EPMC7279645","cross_references":{"pubmed":["32503946"],"doi":["10.1136/jitc-2019-000391"]}}